A broad-spectrum nanobody targeting the C-terminus of the hepatitis B surface antigen for chronic hepatitis B infection therapy
Brief intro:
- Author: YueWang, YaxianMei, ZhenghongAo, YuanzhiChen, YichaoJiang, XiaoqingChen, RuoyaoQi, BaorongFu, JixianTang, MujinFang, MinYou, TianyingZhang, QuanYuan, WenxinLuo, NingshaoXia
- Journal: Antiviral Research
- Doi: https://www.doi.org/10.1016/j.antiviral.2022.105265
- Publication Date: 2022 Mar
Products/Services used in the paper
Quotation shows PackGene:C57BL/6 mice (Shanghai SLAC Laboratory Animal Co., Ltd., China) were injected with HBV/adeno-associated virus (AAV) (HBV–B from PackGene Biotech, HBV-D from Five Plus Molecular Medicine Institute, China) via the caudal vein. HCAb treatment was conducted as previously described
Research Field:liver
AAV Serotype:HBV–B
Animal or cell line strain:C57BL/6 mice
Abstract
Sustainable viral suppression with hepatitis B surface antigen (HBsAg) loss is the new treatment goal for chronic hepatitis B (CHB). The role of antibodies in therapies for persistent hepatitis B virus (HBV) infection has received constant attention. While immunotherapy holds great promise, challenges for the antibody-based prevention and control of HBV in CHB include broad HBV antigenic diversity and the need for long-term viral suppression. In this study, we identified a new anti-HBsAg nanobody (Nb), 125s, isolated from HBsAg-immunized alpaca and confirmed its excellent potency in HBsAg clearance and broad-spectrum therapeutic activity against three HBV subtypes in vivo. In addition, we characterized a novel epitope at the C-terminus of the HBsAg surface motif from amino acids 157 to 174. A 125s-based long-term passive immunization program was efficacious at HBsAg clearance and inducing cellular immune responses, offering a promising outlook for CHB immunotherapy.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
